← Back to Search

Drug Resistance Research for Osteosarcoma

Waitlist Available
Led By John Healey, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with a presumed or known diagnosis of a primary or secondary bone cancer or other solid tumor who are having or have had a biopsy or surgery to remove tumor for diagnostic or therapeutic reasons. No tumors will be obtained solely for research purposes
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial will study how different drugs affect tumors and why some tumors develop high pressure, which can affect how well drugs work. Blood samples will be taken to help predict the behavior of different types of tumors.

Who is the study for?
This trial is for individuals with a presumed or confirmed diagnosis of bone cancer (osteosarcoma) or other solid tumors who are undergoing biopsy or surgery. It's open to adults and minors; adults must consent, while minors give assent and have parental consent.Check my eligibility
What is being tested?
The study aims to understand how osteogenic sarcoma and other solid tumors react to drug therapies by examining tumor tissue and blood samples. Researchers will look into why some tumors resist treatment and the impact of internal tumor pressure on drug effectiveness.See study design
What are the potential side effects?
Since this trial involves tissue procurement rather than testing a new medication, there aren't direct side effects from drugs being studied. However, typical risks associated with biopsies or surgeries may apply.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I have or had a biopsy or surgery for bone or solid tumor cancer diagnosis or treatment.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To test tumor samples obtained from patients with primary or secondary bone cancer for mechanisms of acquired and intrinsic resistance to methotrexate and to relate these findings to histologic response to preoperative chemotherapy and outcome.
Secondary outcome measures
To attempt to grow these tumor cells in short term culture to test the sensitivity of these cells to chemotherapeutic agents and to correlate cytotoxicity with biochemical and molecular studies.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Hospital for Special Surgery, New YorkOTHER
243 Previous Clinical Trials
58,601 Total Patients Enrolled
Weill Medical College of Cornell UniversityOTHER
1,054 Previous Clinical Trials
1,315,765 Total Patients Enrolled
Columbia UniversityOTHER
1,431 Previous Clinical Trials
2,460,068 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there capacity to enroll additional participants in this experiment?

"Contrary to the data hosted on clinicaltrials.gov, it appears that this particular trial is currently not enrolling patients at this time. First posted in August 1997 and last updated in September 2022, though this investigation has stopped seeking participants, there are still 500 other trials actively recruiting now."

Answered by AI
~7 spots leftby Aug 2024